Author: admin

ADMANITY CEO Brian Gregory Unveils YES REPORT, an Agency Branding And Marketing Tool for Small Businesses Taking The YES! TEST, Adding to ADMANITY B2B Tools YES PRESS, YES PAK, PRO PAK and YES BOT.

ADMANITY CEO Brian Gregory Unveils YES REPORT, an Agency Branding And Marketing Tool for Small Businesses Taking The YES! TEST, Adding to ADMANITY B2B Tools YES PRESS, YES PAK, PRO PAK and YES BOT.

“This is your business in a box. It will give you all the strategies you need to run your company for decades. The speed at which our algorithms can deliver the exact formulas and marketing information any company needs is truly mind-blowing, If your customer is a human, we have the tools, methods and systems to show any businessperson exactly what will work to persuade them to buy instantly,” said Brian Gregory.
ADMANITY® CEO, Brian Gregory announced it has added to its suite of YES-branded B2B Marketing tools with The YES REPORT. The newly updated, 150-page YES REPORT joins The YES TEST, YES BOT, YES PRESS, YES MEDIA, PRESS PAK, YES PAK, PRO PAK and other B2B marketing tools for small businesses. The YES REPORT is available only to those who have taken the free, 5-minute YES TEST and gives in-depth, agency-level advice on branding, emotional formulas, strategies, tactics, upsells, copywriting and more.

PHOENIX, ARIZONA – Brian Gregory, CEO for ADMANITY®, based in Phoenix Arizona announced the YES REPORT, an agency-level “Owner’s Manual” that is available only for companies who have taken the free YES TEST available at https://admanity.com/yes-test/. The 150-page YES REPORT is the equivalent of what most agencies could charge $15,000 or more to create for small business clients and entrepreneurs. It reveals the best emotional strategies, tactics and advertising formulas for any brand, including upselling formulas, customer win-back formulas, 16 different advertising formulas, a persuasion library of words, phrases and metaphors for copywriting that converts, customer targeting strategies and more, all at a fraction of the market rate for such a B2B marketing tool.  

“This is your business in a box. It will give you all the strategies you need to run your company for decades,” said Brian Gregory. 

Perhaps even more amazing is that this information is available within minutes, not weeks or months to anyone who takes the YES TEST.  “The speed at which our algorithms can deliver the exact formulas and marketing information any company needs is truly mind-blowing,” said Brian Gregory. 

The new YES REPORT also comes with a newly upgraded section on copywriting, featuring formulas on how to write copy for ads, emails, social media posts and just about any written form of communication. The YES REPORT gives anyone the same advantages and secrets multi-million-dollar ad agencies use every day. The principles outlined in The YES REPORT can even be used in verbal persuasion for sales teams or entrepreneurs using zoom video calls or when selling over the phone or on stage. 

“If your customer is a human, we have the tools, methods and systems to show any businessperson exactly what will work to persuade them to buy instantly,” said Brian Gregory. 

Interested parties are encouraged to visit the company website for more information on not only the YES REPORT for their brand, but also to see the rest of the incredible YES-branded B2B products and tools. For example, YES PAK uses the YES TEST as an amazing lead generation tool with a 90% conversion rate and an incredibly high booking rate for appointments. YES PRESS is the company’s press release syndication B2B tool that gets any business press release on GOOGLE Page one in search results. For companies that haven’t yet been able to harness the power of Press Release PR in search results, it is amazingly low-cost and gets results in one week. YES PRESS can be seen at https://getyespress.com.  

Additional B2B tools include YES MEDIA, which offers over 250 million royalty-free stock videos and over 5 million royalty-free stock videos available only to ADMANITY customers. Other products include PRESS PAK and PRO PAK for agency-level users and YES BOT, an advanced AI chatbot that has expert sales capabilities. “You have to experience YES BOT to believe it. This little chatbot can be customized to any company and its conversation skills exceed most customer service staff. It makes friends with every conversation and its sense of humor helps sell products and services. People don’t feel like they’re being sold when YES BOT sells it. It’s fun and helpful,” said Brian Gregory. 

About ADMANITY and YES Products:

ADMANITY is a Phoenix-based SaaS company specializing in cutting-edge, proprietary B2B products to help small businesses, solopreneurs and entrepreneurs sell, advertise, market and promote their products and services. ADMANITY’s first proprietary algorithms created the YES TEST, followed by lead generation tools such as YES PAK, B2B tools such as YES MEDIA and YES BOT, advertising agency tools such as PRO PAK, press release syndication PR tools such as YES PRESS and PRESS PAK, YES CONNECT for B2B networking and most recently branding and advertising tools such as The YES REPORT. ADMANITY partners with large companies and organizations with a B2B focus to help their business clients. ADMANITY also works with advertising and branding agencies, B2B consultants, coaches and small business owners. ADMANITY is privately held, and was founded by Brian Gregory, CEO and Roy Regalado, President. 

About Brian Gregory:

Brian Gregory, CEO for ADMANITY, is the creator of the algorithms now in use with the world-famous YES TEST. Brian Gregory is the author of 15 books on marketing including the book that led to the development of ADMANITY’s breakthrough emotional algorithms, “Sheep Don’t Eat Complicated Grass!” which is available free digitally if you contact ADMANITY on its website. Brian Gregory is also the Alignable Local Business Person of the Year for 2024, which places him 2nd among over 9 million Alignable members who participated in the Alignable Local Business Person of the Year Contest. Brian Gregory is an expert on emotional marketing and copywriting and has been featured on stages and podcasts around the world.

The YES TEST, YES REPORT, YES PRESS, YES BOT, YES PAK, YES MEDIA, PRESS PAK, and PRO PAK are trade names owned by ADMANITY®, LLC. All rights reserved. 

Media Contact
Company Name: ADMANITY®
Contact Person: Brian Gregory, CEO
Email: Send Email
City: Phoenix
State: Arizona
Country: United States
Website: https://admanity.com

Mohammad Honarkar: A Visionary Leader in Laguna Beach Real Estate

Mohammad Honarkar: A Visionary Leader in Laguna Beach Real Estate

Mo Honarkar
Mohammad (Mo) Honarkar, a prominent real estate investor and entrepreneur, is making significant strides in revitalizing Laguna Beach through his company, 4G Ventures.

Mohammad (Mo) Honarkar, a prominent real estate investor and entrepreneur, is making significant strides in revitalizing Laguna Beach through his company, 4G Ventures. With an impressive portfolio that includes Hotel Laguna, the Art-A-Fair building, Cliff Village LLC, Terra Laguna Beach, and the 14West hotel, Honarkar is at the forefront of transforming the local landscape.

Honarkar’s commitment to urban renewal is reshaping the city’s development standards. His visionary projects aim to create vibrant, mixed-use environments that benefit the community. Known for his dedication to enhancing Laguna Beach’s beauty, Honarkar is actively involved in initiatives that promote a safe and nurturing community atmosphere.

Recent proposals from Honarkar include new hotels and housing complexes designed to meet the needs of residents and visitors alike. As a dedicated family man, he embodies the spirit of community involvement, striving to create a Laguna Beach that is both welcoming and flourishing.

About Mohammad Honarkar

Mohammad Honarkar is a prominent real estate investor and entrepreneur based in Laguna Beach, California. As the founder and CEO of 4G Ventures, he has spearheaded numerous projects that focus on sustainable urban development and revitalization of local landscapes. His extensive property portfolio includes notable assets such as Hotel Laguna, the Art-A-Fair building, and multiple mixed-use developments, reflecting his commitment to enhancing the community.

Honarkar is recognized for his innovative approach to real estate, aiming to set new standards for development in Laguna Beach. He is deeply involved in community initiatives, striving to create vibrant, safe, and nurturing environments for residents and visitors alike.

About Laguna Beach, Ca

Laguna Beach, California, is a picturesque coastal city located in Orange County, known for its stunning beaches, vibrant arts scene, and rich history. With more than 30 coves and beaches, it offers visitors numerous opportunities for outdoor activities, including snorkeling, swimming, and surfing.

The city’s unique charm is enhanced by its artistic community, which has attracted artists and visitors for over a century. Annual events, such as the Pageant of the Masters and the Sawdust Art Festival, celebrate this artistic heritage.

Laguna Beach also features scenic hiking trails and breathtaking coastal views, making it a prime destination for nature lovers. The combination of its natural beauty and cultural richness makes Laguna Beach a beloved spot for both residents and tourists alike.

Mo Honarkar in the News

The Honarkar Foundation – Mohammad Honarkar

Mo Honarkar – Linkedin

Mohammad Honarkar Laguna Beach Entrepreneur

Media Contact
Company Name: The Honarkar Foundation
Contact Person: Mo Honarkar
Email: Send Email
Country: United States
Website: https://www.thehonarkarfoundation.org/mission/

Breaking Mobile Sales Barriers – Mission Control from The Sim Guys Powers Bigger, Better Deals

Breaking Mobile Sales Barriers - Mission Control from The Sim Guys Powers Bigger, Better Deals
Simplify mobile sales – manage SIMs, automate billing, and offer competitive rates with your own white-label End-User portal that gives customers self-service control.

Looking to boost your mobile offerings with competitive wholesale SIM rates and a super-simple way to manage everything? Whether you’re expanding a telecoms business or diving into new revenue streams as an IT reseller, Mission Control from The Sim Guys is here to make things easy, efficient, and (dare we say) fun. Say goodbye to the barriers that make selling and managing mobile services a headache. With Mission Control, everything—from SIM management to billing—can be automated without even touching your existing workflows.

So, what’s the magic behind Mission Control? It brings unbeatable wholesale SIM rates, powerful management tools, and a flexible end-user portal, all wrapped up in one tidy package. This isn’t just a tool—it’s a game-changer. Imagine having full control over your CRM, SIM management, ordering, billing, and ticketing—all in one sleek, white-labelled portal. Now picture giving your customers the ability to manage their own SIMs, check usage, or bar premium numbers! No more clunky systems or endless platforms to juggle. Just seamless, streamlined operations, freeing you up to focus on what really matters—growing your business.

Let’s talk flexibility. Whether you’re integrating with Shopify or customising it to fit your specific business needs, Mission Control adapts like a dream. It doesn’t disrupt what’s already working—it simply takes it up a notch. We’re talking smoother mobile sales, easier SIM management, and stress-free billing. All the nitty-gritty is handled for you, so you can channel your energy into scaling your business and landing those bigger deals. And we’re flexible. Our deep-dive approach allows us to tailor the system specifically for your business—plus, we provide personal customer support whenever you need it.

Worried about losing control? No need. With Mission Control, you keep ownership of your customer base—that’s your bread and butter. And with super-competitive rates and a customer-friendly self-service portal, you’ll be competing with the big players in no time. The white-labelled end-user portal gives your business customers the control and freedom they crave. Imagine bidding on those larger contracts, knowing your systems are running like clockwork. That’s a win.

Best of all, Mission Control fits right into your existing setup. No stress, no mess—just optimised mobile operations and all the tools you need to take your business to the next level. It’s time to bust through the barriers that have been holding you back. This all-in-one solution is ready to streamline your processes and help you win bigger, better deals.

Ready to see what Mission Control can do? Head over to thesimguys.com and discover how to transform your mobile sales. The future of mobile sales management is waiting—let’s go get it!

Media Contact
Company Name: The Sim Guys
Contact Person: Ruth Wilson
Email: Send Email
Country: United Kingdom
Website: https://www.thesimguys.com/

The Official bUMS Soundtrack Debuts, Featuring a Lineup of Tracks by Recording Artist-Producers Jason Raphael, aka Vocab, and Dane Diamond

Featuring an eclectic blend of genres and styles, the bUMS soundtrack is leaving listeners wanting more. bUMS recently launched, receiving perfect ratings from Rotten Tomatoes and on Amazon Prime Video.

Jason Raphael, founder of The Jason Raphael Company, has announced the release of the bUMS official soundtrack. This album ignites emotion at every turn and can be streamed now on leading platforms including Distrokid, Spotify, Deezer, Apple Music, iTunes, and iHeartRadio.

bUMS is a captivating drama that takes audiences into the lives of dAVID (played by Jason Raphael), pETER, fRANK, bROADWAY vIC, mARY, and sUNSHINE, a group of homeless people who are barely hanging on to their humanity after struggling to survive on the streets for decades. They join a government-funded program in an effort to regain their lives. Visceral, raw, and visionary, bUMS is a perfectly written story with flawless acting and exceptional cinematography. The film has amassed a 100% rating on Rotten Tomatoes and perfect reviews on Amazon Prime Video.

Now, the bUMS original soundtrack is further mesmerizing audiences with singles created and produced by recording artist-producers Jason Raphael and Dane Diamond. On one single, “dAVID & fRANK”, Raphael, who raps as Vocab, delivers one blistering verse after another. On the title track “bUMS”, Diamond delivers a ballad that conveys the loss of humanity depicted in the film. Other tracks on the album that are already catching attention include “Make Me Feel So Alive”, “Home”, and “No Place To Go”.

Compelling, thought provoking, and at times, heart wrenching, the bUMS soundtrack offer an impressive variety of genres, themes, and emotional undertones. Listeners are exposed to the human element at every turn, hearing the real and raw emotion in the voices of Vocab and Diamond through each melody and word. Audiences are enjoying listening to the album, whether they’ve seen the film or not, although listening to the bUMS soundtrack is sure to inspire one to see the film.

Stream the soundtrack now at https://distrokid.com/hyperfollow/vocabanddanediamond/bums-original-motion-picture-soundtrack.

ABOUT THE JASON RAPHAEL COMPANY

Based in Los Angeles, California, The Jason Raphael Company is a production studio that develops and produces award-winning original motion-pictures, television, music, and digital content. Follow The Jason Raphael Company on Instagram: @tjrc.film

Media Contact
Company Name: The Jason Raphael Company
Email: Send Email
City: BURBANK
State: CALIFORNIA
Country: United States
Website: https://www.rottentomatoes.com/m/bums

Acromegaly Pipeline Insights and Analysis 2024: FDA Approvals , and Treatment Outlook | Pfizer Inc, Novartis AG, Validus Pharma, Ipsen, Chiasma, Inc, Crinetics Pharma, Ionis Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Acromegaly pipeline constitutes 12+ key companies continuously working towards developing 13+ Acromegaly treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Acromegaly Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acromegaly Market.

 

The Acromegaly Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Acromegaly Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Acromegaly treatment therapies with a considerable amount of success over the years. 

  • Acromegaly companies working in the treatment market are OPKO Health, Amolyt Pharma, Debiopharm International, Glytech, Antisense Therapeutics, Crinetics Pharmaceuticals Inc., Camurus AB, and others, are developing therapies for the Acromegaly treatment 

  • Emerging Acromegaly therapies in the different phases of clinical trials are- MOD-12014, AZP-3813, Debio 4126, GT-02037, ATL1103, Paltusotine, CAM-2029, and others are expected to have a significant impact on the Acromegaly market in the coming years.   

  • In September 2024, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine. This is the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist in development, intended for the proposed treatment and long-term maintenance therapy of acromegaly.

  • In July 2024, Swedish pharmaceutical company Camurus has announced positive outcomes from the Phase III ACROINNOVA 2 study, which evaluated the efficacy and safety of octreotide subcutaneous (SC) depot (CAM2029) in patients with acromegaly. Acromegaly is a gradually progressing condition caused by a pituitary gland tumor that produces excess growth hormone, leading to elevated insulin-like growth factor 1 (IGF-1) levels.

 

Acromegaly Overview

Adults with an uncommon, slowly progressing acquired condition called acromegaly may be affected. It happens when the pituitary gland secretes an excessive amount of growth hormone (GH).

 

Get a Free Sample PDF Report to know more about Acromegaly Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acromegaly-pipeline-insight

 

Emerging Acromegaly Drugs Under Different Phases of Clinical Development Include:

  • MOD-12014: OPKO Health

  • AZP-3813: Amolyt Pharma

  • Debio 4126: Debiopharm International

  • GT-02037: Glytech

  • ATL1103: Antisense Therapeutics

  • Paltusotine: Crinetics Pharmaceuticals Inc.

  • CAM-2029: Camurus AB

 

Acromegaly Route of Administration

Acromegaly pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Acromegaly Molecule Type

Acromegaly Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy 

 

Acromegaly Pipeline Therapeutics Assessment

  • Acromegaly Assessment by Product Type

  • Acromegaly By Stage and Product Type

  • Acromegaly Assessment by Route of Administration

  • Acromegaly By Stage and Route of Administration

  • Acromegaly Assessment by Molecule Type

  • Acromegaly by Stage and Molecule Type

 

DelveInsight’s Acromegaly Report covers around 13+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Acromegaly product details are provided in the report. Download the Acromegaly pipeline report to learn more about the emerging Acromegaly therapies

 

Some of the key companies in the Acromegaly Therapeutics Market include:

Key companies developing therapies for Acromegaly are – Pfizer Inc, Novartis AG, Validus Pharmaceuticals LLC, Ipsen, Chiasma, Inc, Crinetics Pharmaceuticals, Ionis Pharmaceuticals Inc, Midatech Pharma Plc, ADVANZ PHARMA, Amolyt Pharma, and others.

 

Acromegaly Pipeline Analysis:

The Acromegaly pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Acromegaly with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acromegaly Treatment.

  • Acromegaly key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Acromegaly Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acromegaly market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Acromegaly drugs and therapies

 

Acromegaly Pipeline Market Drivers

  • Increasing incidence of pituitary tumors and acromegaly, favorable government insurance policies and schemes are some of the important factors that are fueling the Acromegaly Market.

 

Acromegaly Pipeline Market Barriers

  • However, high cost of treatment, lack of awareness and patient education and other factors are creating obstacles in the Acromegaly Market growth.

 

Scope of Acromegaly Pipeline Drug Insight    

  • Coverage: Global

  • Key Acromegaly Companies: OPKO Health, Amolyt Pharma, Debiopharm International, Glytech, Antisense Therapeutics, Crinetics Pharmaceuticals Inc., Camurus AB, and others

  • Key Acromegaly Therapies: MOD-12014, AZP-3813, Debio 4126, GT-02037, ATL1103, Paltusotine, CAM-2029, and others

  • Acromegaly Therapeutic Assessment: Acromegaly current marketed and Acromegaly emerging therapies

  • Acromegaly Market Dynamics: Acromegaly market drivers and Acromegaly market barriers 

 

Request for Sample PDF Report for Acromegaly Pipeline Assessment and clinical trials

 

Table of Contents

1. Acromegaly Report Introduction

2. Acromegaly Executive Summary

3. Acromegaly Overview

4. Acromegaly- Analytical Perspective In-depth Commercial Assessment

5. Acromegaly Pipeline Therapeutics

6. Acromegaly Late Stage Products (Phase II/III)

7. Acromegaly Mid Stage Products (Phase II)

8. Acromegaly Early Stage Products (Phase I)

9. Acromegaly Preclinical Stage Products

10. Acromegaly Therapeutics Assessment

11. Acromegaly Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acromegaly Key Companies

14. Acromegaly Key Products

15. Acromegaly Unmet Needs

16 . Acromegaly Market Drivers and Barriers

17. Acromegaly Future Perspectives and Conclusion

18. Acromegaly Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acromegaly Pipeline Insights and Analysis 2024: FDA Approvals , and Treatment Outlook | Pfizer Inc, Novartis AG, Validus Pharma, Ipsen, Chiasma, Inc, Crinetics Pharma, Ionis Pharma

bUMS, the New Drama from Jason Raphael, Debuts to Positive Reviews on Rotten Tomatoes and Amazon Prime

This new film is an adaptation of the off-Broadway play “Bums” and chronicles the realities of homelessness and life on the streets.

From the The Jason Raphael Company and the mind, heart, and soul of multi-hyphenate writer, director, producer, and actor Jason Raphael comes bUMS. This unforgettable drama has made its official debut and has already received wide acclaim, including a perfect 100% score on Rotten Tomatoes and a perfect five-star rating on Amazon Prime Video.

Jason Raphael has established himself as a new major American filmmaker, honing in on his talents for truthfully conceptualizing and conveying a story through stunning cinematography, compelling writing, and pitch-perfect acting. According to Robert Shaffron, playwright, “Jason Raphael has created a true American masterpiece…the best debut I’ve seen in decades.”

Leading his cast of newcomers, Jason Raphael excels throughout this visionary piece, giving a heartbreaking and searing tour-de-force as dAVID. It is a performance that immediately establishes Raphael as a prodigious acting talent in film. Rounding out the main cast of characters are pETER, fRANK, bROADWAY vIC, mARY, and sUNSHINE, a group of homeless people who are barely hanging on to their humanity after struggling to survive on the streets for decades. They join an ambitious new government-funded program in the hopes of regaining their lives. The Jason Raphael Company is thrilled to have created this visceral, raw story that is captivating audiences everywhere.

Watch the trailer and get access to the film now by visiting https://www.rottentomatoes.com/m/bums.

ABOUT THE JASON RAPHAEL COMPANY

Based in Los Angeles, California, The Jason Raphael Company is a production studio that develops and produces award-winning original motion-pictures, television, music, and digital content. Follow The Jason Raphael Company on Instagram: @tjrc.film

Media Contact
Company Name: The Jason Raphael Company
Email: Send Email
City: BURBANK
State: CALIFORNIA
Country: United States
Website: https://www.rottentomatoes.com/m/bums

Dance Music 4 Democracy (DM4D) Launches to Spur Voter Registration Among EDM Fans; Celebrity Event at the Mint Los Angeles October 16

As our country heads towards its most momentous and consequential election in decades, by the Internal Revenue Service (IRS). 

DM4D believes they can leverage the power of dance music to protect the country’s most sacred democratic institutions. DM4D is already establishing its presence and organizing its outreach, producing and promoting dance music events around the country, with free or discounted entry  subject to availability and voter registration offered on site and online. By expanding the breadth of voices that can be heard in US voting booths every year, DM4D hopes to spread a love of democracy and individual freedoms the same way dance music has successfully spread a love of what makes us all human. DM4D has partnered with HeadCount, one of the nation’s leading voter registration organizations that has registered more than 1.2 million voters since 2004, to enable event attendees to register to vote both online from the web site

 and in-person at DM4D events, the first of which takes place October 16 at the Mint in Los Angeles.

DM4D launches with Beats for Change at historic venue The Mint in Los Angeles from 8PM October 16, with live DJ sets from pioneering DJ Kristina Sky, DJ Karmå and Vassal States, a tribute to the beloved DJ Danny Stubbs, whose recent passing stunned the dance music community; and more special guests to be announced. The show is 18+ to reach that critical voter demographic. The Mint is located at 6010 West Pico Blvd, Los Angeles, CA 90035. Tickets can be purchased here.

Celebrity guests include (in alphabetical order):

Cinematographer Akis Konstantakopoulos (The Chosen); Alexander Parlee and The Ellipses (Musician new single “Raised in the Woods”); Heather Medway (THE FEAR series; VIPER); Bobbie Carradine (REVENGE OF THE NERDS); Brett Pierce (Stuck in the MIddle, Imaginary Mary); Bourke Floyd  (Dawson’s Creek); director Carlos Carrera; Christian Try (musician new single “Be the Light” produced by Danny Stubbs); De’voreaux White (DIE HARD, Obliterated); Danny Medici (ANYWHERE BUT HERE); Eddie Bowz (NYPD Blue); Eric and Eliza Roberts; DJ Kristina Sky; DJ Karmå; Roger Rose; Rosanna Arquette(DESPERATELY SEEKING SUSAN; PULP FICTION); TikTok influencer 2.2m Sam Vicchiollo; Sheridan Pierce (Dear White People) and DJ’s Vassal States.

Dance Music for Democracy’s mission is to bring together advocates, creators, lovers, and warriors of all ages, races, genders, sexualities, and religions to defend the right of each of us to be seen and heard. By bringing dance music to the people, DM4D hopes to bring the people to the polls, addressing the issues of low voter registration and turnout by producing one-of-a-kind, live dance music events. With free and discounted entry where available, on-site voter registration tables grant newly minted and experienced voters alike access to some of the highest-quality live DJ sets in the nation.   All of this in works concert with targeted digital outreach across social, streaming, video, and podcasts to get out the vote.

Through grassroots fundraising, a generous donor base, and support from DJ’s and celebrities, DM4D  hopes to energize the dance music community to stand up for every individual’s right to choose their representatives—and their future—for themselves, dancing their way into participating in one of the most revolutionary yet enduring systems of government in the world: the United States’ 248-year-old democracy.

DM4D is the brainchild of Board President Greg H. Sims, an independent film producer, financier, and artist manager with a history of providing early opportunities for some of the industry’s top names, including George Clooney, Amanda Peet, Michael Vartan, Tom Sandoval, and cinematographer John Schwartzman. He received Certified Platinum awards working with Dutch superstar Anouk. Sims has also long been active in the electronic music scene, having worked closely with luminaries like Armin van Buuren, Paul Oakenfold, and Gareth Emery. Besides those, his favorite DJ’s include Martin Garrix, Danny Avila, Odesza, Diplo, Rezz, and Kristina Sky.

Through wide-ranging discussions with politicians and pundits from all political stripes and with the support of DJ’s and other dance music artists, Sims recognized there is tremendous power in dance music to excite crowds, bringing people out en masse to support the ideals they cherish, like peace, love, unity, and respect. He says, “There’s no question many potential voters have become numb to politics and voting, and while I somewhat understand that, I don’t accept that as the final word. What better way than through music to engage and inspire people to come out in force to defend the institutions that support our right as Americans to live freely according to those ideals?”

Sims is joined on the DM4D Board by longtime financial executive, business advisor, and entrepreneur Nick Mayberry, whose clients have included Adobe, Comcast, Credit Karma, and Google. Mayberry’s favorite DJs include Aluna, D.O.D, Sonny Fodera, Tensnake, and The Blessed Madonna. Other board members include longtime tour manager Art Cisneros, who’s worked with such artists as Neil Diamond, Barry Manilow, Ann-Margret, Barbara Streisand, Jane’s Addiction, Luis Miguel, k.d. lang, Colbie Caillat, Adam Lambert, David Cook, David Lee Roth (Van Halen) and The Go-Go’s; film sales and distribution executive Brett Leitner, who’s worked for New Line Cinema and HBO before becoming Head of Distribution at Music Choice; and actor and broadcaster Roger Rose, scion of the broadcasting family that includes father Hilly Rose and brother Judd Rose.

Cisneros’ favorite DJs include Alesso, David Guetta, Tiësto, Avicii, Calvin Harris, and Zedd. Leitner claims DJ Jellybean Benitez “I’m old school!” David Guetta and Avicii among his favorite DJ’s.

Can’t make one of our events? No problem. Prospective voters can register to vote right from the DM4D web site without even attending an event.

Media Contact
Company Name: Platformgrp
Contact Person: Henry Eshelman
Email: Send Email
Country: United States
Website: https://platformgrp.com/

Magic Unleashed in Small-Town America: J.L. Knight’s Glintborn Fools Brings a Thrilling New YA Fantasy Adventure

Magic Unleashed in Small-Town America: J.L. Knight’s Glintborn Fools Brings a Thrilling New YA Fantasy Adventure
Adventure is dangerously close to home in J.L. Knight’s highly anticipated debut novel, “Glintborn Fools,” the first in the electrifying Glintborn series. Perfect for fans of Holly Black, Samantha Shannon, and Lauren Roberts, this young adult contemporary fantasy plunges readers into the mysterious and magical world of Colville, Washington, where nothing is as it seems.

In Glintborn Fools, 18-year-old Aria and her classmates Claire, Sorin, and Michael find their lives upended when a crack in the sky brings a downpour of magic into their sleepy town. As they begin to manifest supernatural powers, a deadly creature with dark intentions sets its sights on Aria. Together, they must unravel the mystery of the shattered sky and stop the creature before it’s too late. With a mix of danger, romance, and magic, Glintborn Fools is a captivating journey that will keep readers hooked from the first page to the last.

J.L. Knight, a former game designer turned young adult author, weaves a rich and complex tale that balances real-world challenges with a fantastical adventure. Knight is known for her vivid world-building and the seamless way she incorporates mythical creatures, supernatural powers, and contemporary themes. Glintborn Fools touches on issues like chronic illness, family secrets, and class divides, all set against the backdrop of a gripping magical mystery.

Early reviews are already raving about Glintborn Fools. Literary Titan praises the novel as “a captivating read that kept me hooked from the very first page” and highlights the novel’s “epic, fantastical adventures happening in the most unsuspecting places.” The review also notes Knight’s expert handling of mythical creatures, from vampires and elves to dragons and fauns, creating a tense and thrilling narrative that promises to keep readers on the edge of their seats.

The characters, too, have drawn praise for their depth and complexity. Aria, who has long battled an autoimmune disease, is miraculously cured when magic enters her life, while her friends Michael, Claire, and Sorin each gain their own unique abilities. Together, they must face not only the threat of a sinister vampire but also uncover the dark secrets lurking within their own families.

With its heart-pounding adventure, complex characters, and blend of magic and real-world themes, Glintborn Fools is sure to be a hit among fans of young adult fantasy. Glintborn Fools is available now on Kindle, audiobook and in paperback on Amazon and Barnes & Noble, with the second book in the series, Glintborn Magician, available for preorder.

Reader Reviews:

★★★★★ “Lots of fun characters/perspectives, cool magic . . . can’t wait for more”

★★★★★ “Simply magical . . . an excellent debut!”

★★★★★ “If you enjoy romance, magic, and vampires, there’s a lot to love”

★★★★★ “The magic envelopes you . . . just like the glint!”

★★★★★ “Don’t skip this triumphant debut work!”

About the Author

J.L. Knight is a Pacific Northwest-based author and former game designer who crafts immersive and dynamic young adult fantasy stories. With a passion for blending real-world challenges with magical realms, she brings readers on thrilling adventures that explore themes of power, identity, and personal growth. Her debut novel, Glintborn Fools, is the first in the Glintborn series.

Inspired by the works of authors like Holly Black, Sarah J. Maas, and Rebecca Ross, Knight’s storytelling is known for its intricate world-building and fast-paced plots. She seamlessly combines dark magic, mythical creatures, and gripping mysteries to create narratives that resonate with teen and adult readers alike.

When not writing, Knight enjoys reading fantasy novels and spending time with her husband and two children. She continues to expand the Glintborn universe, with the second book in the series, Glintborn Magician, currently available for preorder.

Media Contact
Company Name: Literary Titan
Contact Person: J.L. Knight
Email: Send Email
Country: United States
Website: https://www.glintbornbooks.com/

NorCal Pain Treatment Center Offers Relief with Trigger Point Injections

“Trigger Point Injections Norcal Paint Treatment Center Turlock”

Turlock, CA – Oct 15, 2024 – NorCal Pain Treatment Center is pleased to announce the addition of trigger point injections to its comprehensive range of pain management services. This innovative treatment option provides targeted relief for individuals suffering from chronic pain conditions.

Trigger point injections are a minimally invasive procedure that involves injecting a local anesthetic and corticosteroid into painful areas known as trigger points. These trigger points are areas of muscle tension that can cause referred pain to other parts of the body. By addressing these points, trigger point injections can significantly reduce pain and improve overall function.

“We are excited to offer trigger point injections as a valuable tool for our patients,” said Brenda Lindenberg, VP of Operations at NorCal Pain Treatment Center. “This procedure can provide significant relief for those who have been struggling with chronic pain.”

Trigger point injections are often used to treat conditions such as:

  • Myofascial pain syndrome
  • Fibromyalgia
  • Headaches
  • Neck and shoulder pain
  • Back pain
  • Temporomandibular joint (TMJ) disorder

NorCal Pain Treatment Center is committed to providing compassionate and effective pain management care. Our experienced team of healthcare professionals is dedicated to helping patients achieve a better quality of life.

To learn more about trigger point injections or to schedule a consultation, please contact NorCal Pain Treatment Center at 209.448.3000 or visit our website at www.norcalpain.com

About NorCal Pain Treatment Center

NorCal Pain Treatment Center is a leading provider of pain management services in Turlock, CA. Our goal is to help patients find relief from chronic pain and improve their overall quality of life. We offer a variety of treatments, including interventional pain management procedures, physical therapy, and medication management.

Media Contact
Company Name: NorCal Pain Treatment Center
Contact Person: Brenda Lindenberg
Email: Send Email
Phone: 209.448.3000
Address:1739 Colorado Ave.
City: Turlock
State: CA
Country: United States
Website: https://www.norcalpain.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NorCal Pain Treatment Center Offers Relief with Trigger Point Injections

Bronchopulmonary Dysplasia Pipeline Status 2024: Clinical Trials Overview, MOA, ROA by DelveInsight | Chiesi Farmaceutici S.p.A., AyuVis Research, Airway Therapeutics, Inc, Meridigen Biotech, Medipost

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Bronchopulmonary Dysplasia pipeline constitutes 12+ key companies continuously working towards developing 12+ Bronchopulmonary Dysplasia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Bronchopulmonary Dysplasia Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bronchopulmonary Dysplasia Market.

 

The Bronchopulmonary Dysplasia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Bronchopulmonary Dysplasia Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Bronchopulmonary Dysplasia treatment therapies with a considerable amount of success over the years. 

  • Bronchopulmonary Dysplasia companies working in the treatment market are Chiesi Farmaceutici S.p.A., AyuVis Research, Airway Therapeutics, Inc, Meridigen Biotechnology, Medipost Co., Ltd., Oak Hill Bio Ltd., Mallinckrodt, The Emmes Company, LLC, Medipost Co Ltd., and others, are developing therapies for the Bronchopulmonary Dysplasia treatment 

  • Emerging Bronchopulmonary Dysplasia therapies in the different phases of clinical trials are- OHB-607, AVR-48, AT-100, UMC119-01, Pneumostem, OHB-607, INOmax, Furosemide Cohort 1, Inhaled Nitric Oxide, PNEUMOSTEM®, Curosurf, and others are expected to have a significant impact on the Bronchopulmonary Dysplasia market in the coming years.   

  • In April 2024, EXO Biologics aims to obtain conditional market approval from the European Medicines Agency (EMA) for its bronchopulmonary dysplasia (BPD) preventative, EXOB-001, in preterm newborns, pending the success of its Phase I/II trial.

  • In January 2024, Chiesi Farmaceutici SpA (“Chiesi Group”), a globally recognized biopharmaceuticals and healthcare organization with a focus on research, and Oak Hill Bio, a clinical-stage company specializing in neonatology and rare disease therapeutics, have officially entered into a License and Development Agreement. This collaboration aims to develop, produce, and bring to market OHB-607, an investigational drug designed to address complications associated with extremely premature birth. OHB-607 comprises a recombinant form of insulin-like growth factor-1 (IGF-1) combined with its binding protein, formulated to prevent bronchopulmonary dysplasia in preterm infants. IGF-1 plays a crucial role in fetal organ growth and development, with mothers being the primary source of this growth factor until approximately 30 weeks gestational age.

 

Bronchopulmonary Dysplasia Overview

Bronchopulmonary dysplasia (BPD) is a chronic lung disease that primarily affects premature infants, especially those born very early, usually before 28 weeks of gestation. This condition is a consequence of lung injury and inflammation, often resulting from the use of mechanical ventilation and oxygen therapy, which are common interventions in the care of premature infants with respiratory distress syndrome.

 

Get a Free Sample PDF Report to know more about Bronchopulmonary Dysplasia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-pipeline-insight

 

Emerging Bronchopulmonary Dysplasia Drugs Under Different Phases of Clinical Development Include:

  • OHB-607: Chiesi Farmaceutici S.p.A.

  • AVR-48: AyuVis Research

  • AT-100: Airway Therapeutics, Inc

  • UMC119-01: Meridigen Biotechnology

  • Pneumostem: Medipost Co., Ltd.

  • OHB-607: Oak Hill Bio Ltd.

  • INOmax: Mallinckrodt

  • Furosemide Cohort 1: The Emmes Company, LLC

  • Inhaled Nitric Oxide: Mallinckrodt

  • PNEUMOSTEM®: Medipost Co Ltd.

  • Curosurf: Chiesi Farmaceutici S.p.A.

 

Bronchopulmonary Dysplasia Route of Administration

Bronchopulmonary Dysplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Inhalation

  • Inhalation/Intravenous/Oral

  • Intranasal

  • Intravenous

  • Intravenous/ Subcutaneous

  • NA

  • Oral

  • Oral/intranasal/subcutaneous

  • Parenteral

  • Subcutaneous

 

Bronchopulmonary Dysplasia Molecule Type

Bronchopulmonary Dysplasia Products have been categorized under various Molecule types, such as

  • Antibody

  • Antisense oligonucleotides

  • Immunotherapy

  • Monoclonal antibody

  • Peptides

  • Protein

  • Recombinant protein

  • Small molecule

  • Stem Cell

  • Vaccine

 

Bronchopulmonary Dysplasia Pipeline Therapeutics Assessment

  • Bronchopulmonary Dysplasia Assessment by Product Type

  • Bronchopulmonary Dysplasia By Stage and Product Type

  • Bronchopulmonary Dysplasia Assessment by Route of Administration

  • Bronchopulmonary Dysplasia By Stage and Route of Administration

  • Bronchopulmonary Dysplasia Assessment by Molecule Type

  • Bronchopulmonary Dysplasia by Stage and Molecule Type

 

DelveInsight’s Bronchopulmonary Dysplasia Report covers around 12+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Bronchopulmonary Dysplasia product details are provided in the report. Download the Bronchopulmonary Dysplasia pipeline report to learn more about the emerging Bronchopulmonary Dysplasia therapies

 

Bronchopulmonary Dysplasia Pipeline Analysis:

The Bronchopulmonary Dysplasia pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Bronchopulmonary Dysplasia with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchopulmonary Dysplasia Treatment.

  • Bronchopulmonary Dysplasia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Bronchopulmonary Dysplasia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchopulmonary Dysplasia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Bronchopulmonary Dysplasia drugs and therapies

 

Bronchopulmonary Dysplasia Pipeline Market Drivers

  • Increased Research and Development Activities, new and developed Robust Pipeline are some of the important factors that are fueling the Bronchopulmonary Dysplasia Market.

 

Bronchopulmonary Dysplasia Pipeline Market Barriers

  • However, complications with available treatment options, no Bronchopulmonary Dysplasia approved therapy, lack of a reliable methods for identifying pediatric patients at risk and other factors are creating obstacles in the Bronchopulmonary Dysplasia Market growth.

 

Scope of Bronchopulmonary Dysplasia Pipeline Drug Insight    

  • Coverage: Global

  • Key Bronchopulmonary Dysplasia Companies: Chiesi Farmaceutici S.p.A., AyuVis Research, Airway Therapeutics, Inc, Meridigen Biotechnology, Medipost Co., Ltd., Oak Hill Bio Ltd., Mallinckrodt, The Emmes Company, LLC, Medipost Co Ltd., and others

  • Key Bronchopulmonary Dysplasia Therapies: OHB-607, AVR-48, AT-100, UMC119-01, Pneumostem, OHB-607, INOmax, Furosemide Cohort 1, Inhaled Nitric Oxide, PNEUMOSTEM®, Curosurf, and others

  • Bronchopulmonary Dysplasia Therapeutic Assessment: Bronchopulmonary Dysplasia current marketed and Bronchopulmonary Dysplasia emerging therapies

  • Bronchopulmonary Dysplasia Market Dynamics: Bronchopulmonary Dysplasia market drivers and Bronchopulmonary Dysplasia market barriers 

 

Request for Sample PDF Report for Bronchopulmonary Dysplasia Pipeline Assessment and clinical trials

 

Table of Contents

1. Bronchopulmonary Dysplasia Report Introduction

2. Bronchopulmonary Dysplasia Executive Summary

3. Bronchopulmonary Dysplasia Overview

4. Bronchopulmonary Dysplasia- Analytical Perspective In-depth Commercial Assessment

5. Bronchopulmonary Dysplasia Pipeline Therapeutics

6. Bronchopulmonary Dysplasia Late Stage Products (Phase II/III)

7. Bronchopulmonary Dysplasia Mid Stage Products (Phase II)

8. Bronchopulmonary Dysplasia Early Stage Products (Phase I)

9. Bronchopulmonary Dysplasia Preclinical Stage Products

10. Bronchopulmonary Dysplasia Therapeutics Assessment

11. Bronchopulmonary Dysplasia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Bronchopulmonary Dysplasia Key Companies

14. Bronchopulmonary Dysplasia Key Products

15. Bronchopulmonary Dysplasia Unmet Needs

16 . Bronchopulmonary Dysplasia Market Drivers and Barriers

17. Bronchopulmonary Dysplasia Future Perspectives and Conclusion

18. Bronchopulmonary Dysplasia Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bronchopulmonary Dysplasia Pipeline Status 2024: Clinical Trials Overview, MOA, ROA by DelveInsight | Chiesi Farmaceutici S.p.A., AyuVis Research, Airway Therapeutics, Inc, Meridigen Biotech, Medipost